HTG Molecular (HTGM) announced it has amended its IVD test development and component supply agreement with Illumina (ILMN), previously amended in June 2017, to enable the expansion of potential fields for development and commercialization of IVD test kits for use with HTG EdgeSeq and Illumina sequencing technology. Under the amended agreement, HTG may now submit potential development plans to Illumina for consideration of approval in the fields of autoimmune, cardiovascular, and fibrosis disorders and diseases, in addition to development plans in the oncology field.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.